Navigation Links
Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas
Date:4/11/2011

BURLINGTON, Mass., April 11, 2011 /PRNewswire/ -- Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced today that it has installed the first of its OCT Imaging Systems (OCTIS™) at the University of Texas Medical Branch (UTMB) in Galveston, Texas.

This first system sale will be for research use in the laboratory of Dr. Massoud Motamedi, Director, Center for Biomedical Engineering at UTMB. Dr. Motamedi will be conducting research on application of OCT in intraluminal imaging.

Dr Motamedi said, "There is a great need for the development of a high resolution image-based technique for non-invasive assessment of tissue morphology within the intraluminal space in order to assess changes that may occur in tissue morphology in response to therapeutic interventions or disease progression. The Tomophase OCT system provides the capabilities that are needed to rapidly acquire high-resolution OCT images in the lung, colon and GI tract in human and in various animal models. This imaging system could provide details about tissue morphology and structure that could potentially significantly improve early detection of diseases such as epithelial neoplasm as well as assessment of epithelial integrity and treatment safety and efficacy."

"We are pleased that our state-of-the-art OCT tissue imaging system meets the needs of the University of Texas. High resolution tissue imaging is the focus of our efforts at Tomophase," said Ralph Johnston, President, and COO.

"Our company is committed to providing new, innovative tissue imaging systems to improve the management of pulmonary disease. It is gratifying to see a group such as UTMB, with so much experience in Interventional Pulmonology imaging, choose our OCTIS system," said Peter Norris, PhD CEO.

About UTMB Biomedical Engineering

Established in 1891, Texas' academic health center comprises four health sciences schools, three institutes for advanced study, a research enterprise that includes one of only two national laboratories dedicated to the safe study of infectious threats to human health, and a health system offering a full range of primary and specialized medical services throughout Galveston County and the Texas Gulf Coast region. UTMB is a component of the University of Texas System and a member of the Texas Medical Center.

About Tomophase

Tomophase Corporation is a privately held opto-medical device company with a proprietary position in real-time, high-resolution, cross-sectional tissue imaging using a variant of OCT. Our goal is to provide physicians with heretofore unobtainable airway microstructural images to improve the management and clinical outcome of pulmonary disease. Examples of our tissue imaging results are available at http://www.tomophase.com.

For further information:

Dr. Peter Norris, CEO
Tomophase Corporation
P: (781) 229-5700
E: pnorris@tomophase.com

Ralph Johnston, President, COO
Tomophase Corporation
P: (781) 229-5700
E: rjohnston@tomophase.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Tomophase Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tomophase Receives Qualifying Therapeutic Discovery Project (QTDP) Award
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... IPSWICH, Mass. , Feb. 17, 2017 /PRNewswire/ ... a small tumor had a mutation-conferring resistance to ... treatment. Recently, genomics research has focused on finding ... — or even from circulating tumor DNA in ... identify new oncology therapeutics. Unfortunately, however, ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched work ... agricultural industry. Pilot studies are about to get under way for the framework, which ... 5G innovations. The concept is expected to be transferred eventually to other industries that ...
(Date:2/16/2017)... and GREENWICH, Conn. , ... investment firm focused on venture growth investments in ... of Josh Richardson , M.D. to Managing ... in biotechnology companies.  He is a board observer ... roles in Longitude,s investments in Aimmune Therapeutics, Akebia ...
(Date:2/16/2017)... Research and Markets has announced the addition ... to their offering. ... The study scope includes ... chassis organisms, synthetic cells, production systems), enabling technologies (DNA ... specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):